论文部分内容阅读
The title compound, C15H30N2PdCl2 (Mr=427.73), crystallizes in two kinds of crystal forms I and II.I : monoclinic, P21/c, a = 8.234(1), b = 13.702(3), c = 8.939(2) A, β = 93.90(1)°, V = 1010.55 A3, DC = 1.407g/cm3, R = 0.032 for 2098 observed reflections.II: triclinic, Pl, a=8.179(1), b=8.182(1). c=8.231(2) A, α=91.89(1)°, β=91.90(2)°, α=113.80(1)°, V =503.09A3, DC =1.413 g/cm3, R = 0.036 for 1770 observed reflections.The molecules in both crystals I and II possess the identical configurations but there are two orientations of molecules in the crystal II.
Crystallization in two kinds of crystal forms I and II.I: monoclinic, P21 / c, a = 8.234 (1), b = 13.702 (3), c = 8.939 (2) The title compound, C15H30N2PdCl2 (Mr = 427.73) A, β = 93.90 (1) °, V = 1010.55 A3, DC = 1.407g / cm3, R = 0.032 for 2098 observed reflections .II: triclinic, Pl, a = 8.179 (1), b = 8.182 (1). α = 113.80 (1) °, V = 503.09A3, DC = 1.413 g / cm3, R = 0.036 for 1770 reflections.The molecules in both crystals I and II possess the identical configurations but there are two orientations of molecules in the crystal II.